Transplantation of the sensitized patient: Histocompatibility testing

Methods in Molecular Biology

Volumn 1034, Issue , 2013, Pages 117-125

  Montgomery, Robert A ^a   Leffell, Mary S ^a   Zachary, Andrea A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody monitoring; CDC crossmatch; Desensitization; Flow cytometric crossmatch; Kidney paired donation; Risk assessment; Sensitized patients; Solid phase immunoassays; Virtual crossmatch

Indexed keywords

ANTIBODY;

ACCURACY; ANTIBODY DETECTION; DONOR SELECTION; GRAFT RECIPIENT; HEALTH CARE QUALITY; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; HLA TYPING; HUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIZATION; SURGICAL RISK; TRANSPLANTATION; TREATMENT PLANNING;

EID: 84883215333     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-493-7_6     Document Type: Review

References (38)

1. Montgomery RA, Lonze BE, Jackson AM (2011) Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients. Curr Opin Organ Transplant 16:439-443
2. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH et al (2008) Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359:242-251
3. Lai CH, Cao K, Ong G, Naim M, Wang Q, Mirocha J et al (2011) Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 92:48-53
4. Alachkar N, Lonze BE, Zachary AA, Holechek MJ, Schillinger K, Cameron AM et al (2012) Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 94:165-171
5. Montgomery RA, Zachary AA (2004) Transplanting patients with a positive donorspecific crossmatch: A single center's perspective. Pediatr Transplant 8:535-542
6. Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchaliiska D et al (2003) Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 76:1519-1525
7. Zachary AA, Montgomery RA, Leffell MS (2005) Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 66:364-370
8. Zachary AA, Sholander JT, Houp JA, Leffell MS (2009) Using real data for a virtual crossmatch. Hum Immunol 70:574-579
9. Ferrari P, Fidler S, Holdsworth R, Woodroffe C, Tassone G, Watson N, Cantwell L, Bennett G, Thornton A, Christiansen FT, D'Orsogna L (2012) High transplant rates of highly sensitized recipients with virtual crossmatching in kidney paired donation. Transplantation 94:744-749
10. Ellis TM, Schiller JJ, Roza AM, Cronin DC, Shames BD, Johnson CP (2012) Diagnostic accuracy of solid phase HLA antibody assays for prediction of crossmatch strength. Hum Immunol 73:706-710
11. Tait BD (2009) Solid phase assays for HLA antibody detection in clinical transplantation. Curr Opin Immunol 21:573-577
12. Waterboer T, Sehr P, Pawlita M (2006) Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 309:200-204
13. Zachary AA, Lucas DP, Detrick B, Leffell MS (2009) Naturally occurring interference in Luminex ® assays for HLA-specific antibodies: Characteristics and resolution. Hum Immunol 70:496-501
14. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D (2011) HLA antibody specification using single-antigen beads -technical solution for the prozone effect. Transplantation 92:510-515
15. Butch AW (2000) Dilution protocols for detection of hook effects/prozone phenomenon. Clin Chem 46:1719
16. Zachary AA, Vega RM, Lucas DP, Leffell MS (2012) HLA antibody detection and characterization by solid phase immunoassays: Methods and pitfalls. Methods Mol Biol 882:289-308
17. Jackson AM, Leffell MS, Montgomery RA, Zachary AA (2012) A GPS for fi nding the route to transplantation of the sensitized patient. Curr Opin Organ Transplant 17:433-439
18. Montgomery RA (2010) Renal transplantation across HLA and ABO antibody barriers: Integrating paired donation into desensitization protocols. Am J Transplant 10:449-457
19. Zachary AA, Montgomery RA, Jordan SC, Reinsmoen NL, Claas FHJ, Reed EF (2007) 14th International HLA and immunogenetics workshop: Report on understanding antibodies in transplantation. Tissue Antigens 69(S1):160-173
20. Zachary A, Reinsmoen NL (2011) Quantifying HLA-specific antibodies in patients undergoing desensitization. Curr Opin Organ Transplant 16:410-415
21. Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M et al (2008) Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86:820-825
22. Cecka JM, Terasaki PI (1994) Repeating HLA antigen mismatches in renal transplants -a second class mistake? Transplantation 57:515-519
23. Opelz G (1995) Repeated HLA mismatches increase the failure rate of second kidney transplants. Collaborative Transplant Study. Transplant Proc 27:658-659
24. Claas FHJ, Dankers MK, Oudshoorn M, van Rood JJ, Mulder A, Roelen D et al (2005) Differential immunogenicity of HLA mismatches in clinical transplantation. Transpl Immunol 14:187-191
25. Wissing KM, Fomegné G, Broeders N, Ghisdal L, Hoang AD, Mikhalski D et al (2008) HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 85:411-416
26. Duquesnoy RJ (2011) Humoral alloimmunity in transplantation: Relevance of HLA epitope antigenicity and immunogenicity. Front Immunol 2:106
27. Tambur AR, Leventhal JR, Friedewald JJ, Ramon DS (2010) The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 90:1117-1124
28. Deng CT, El-Awar N, Ozawa M, Cai J, Lachmann N, Terasaki PI (2008) Human leukocyte antigen class II DQ alpha and beta epitopes identifi ed from sera of kidney allograft recipients. Transplantation 86:452-459
29. Zachary AA, Kopchaliiska D, Montgomery RA, Leffell MS (2007) HLA-specific B cells: I. A method for their detection, quantification, and isolation using HLA tetramers. Transplantation 83:982-988
30. Zachary AA, Kopchaliiska D, Montgomery RA, Melancon JK, Leffell MS (2007) HLAspecific B cells: II. Application to transplantation. Transplantation 83:989-994
31. Zachary AA, Lucas DP, Montgomery RA, Leffell MS (2013) Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation 95(5):701-704
32. Locke JE, Zachary AA, Warren DS, Segev DL, Houp JA, Montgomery RA, Leffell MS (2009) Proinfl ammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 9:2136-2139
33. Mohamed MA, Muth B, Vidyasagar V, Foley D, Fernandez L, Hofmann RM et al (2011) Post-transplant DSA monitoring may predict antibody-mediated rejection in sensitized kidney transplant recipients. Clin Transpl 2011:389-394
34. Leffell MS, Zachary AA (2010) Antiallograft antibodies: Relevance, detection, and monitoring. Curr Opin Organ Transplant 15:2-7
35. Dragun D, Philippe A, Catar R (2012) Role of non-HLA antibodies in organ transplantation. Curr Opin Organ Transplant 17:440-445
36. Jackson AM, Lucas DP, Melancon JK, Desai NM (2011) Clinical relevance and IgG subclass determination of non-HLA antibodies identifi ed using endothelial cell precursors isolated from donor blood. Transplantation 92:54-60
37. Lil, Sigdel T, Vitalone M, Lee SH, Sarwal M (2010) Differential immunogenicity and clinical relevance of kidney compartment specific antigens after renal transplantation. J Proteome Res 9:6715-6721
38. Zhang Q, Reed EF (2010) Non-MHC antigenic targets of the humoral response in transplantation. Curr Opin Immunol 22:682-688